GlaxoSmithKline Pharma appoints Dr Shalini Menon as Executive Vice President - Medical Affairs

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has appointed Dr. Shalini Menon as Executive Vice President - Medical Affairs, effective 8th July 2024. She will be part of the Senior Management team of the Company.

Dr. Menon's appointment follows the forthcoming retirement of Dr. Rashmi Hegde, the current Executive Vice President - Medical Affairs, who is set to retire on July 31, 2024.

"In compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform you that the Dr. Shalini Menon has been appointed as Executive Vice President - Medical Affairs, effective 8th July 2024. She will be part of the Senior Management team of the Company. Further, we also wish to inform you that Dr. Rashmi Hegde, current Executive Vice President - Medical Affairs would retire w.e.f 31st July 2024," the Company stated in a BSE filing.

The newly appointed Dr Shalini brings with her 18 years of experience in Medical Affairs with expertise and key contributions in strategic prelaunch planning and therapy shaping by addressing unmet needs, building strong cross-functional working relationships, team building, establishing trusted partnerships with external stakeholders and leading Diversity & Inclusion initiatives amongst others.

Prior to joining GSK, she worked at Sanofi since 2015 and led the Medical team there as Country Medical Head for the last 6 years. Dr Shalini began her career in 2006 at Pfizer and went on to role of Senior Medical Advisor and Lead, Clinical development. She moved from Pfizer to Boehringer Ingelheim in 2011, to launch Diabetes portfolio as Head of Medical affairs, Diabetes & Medical Information.

She holds degrees in MBBS, MD, DNB in Pharmacology from Seth GS Medical college & KEM Hospital Mumbai. She also has a Masters in Pharmaceutical medicine from Hibernia University Dublin.

Read also: GSK pharma Gets CDSCO Panel Nod To study Respiratory Syncytial Virus vaccine RSVPreF3 OA